{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T20:15:05Z","timestamp":1768767305407,"version":"3.49.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T00:00:00Z","timestamp":1616544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T00:00:00Z","timestamp":1616544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Distinguishing bladder urothelial carcinomas from prostate adenocarcinomas for poorly differentiated carcinomas derived from the bladder neck entails the use of a panel of lineage markers to help make this distinction. Publicly available The Cancer Genome Atlas (TCGA) gene expression data provides an avenue to examine utilities of these markers. This study aimed to verify expressions of urothelial and prostate lineage markers in the respective carcinomas and to seek the relative importance of these markers in making this distinction. Gene expressions of these markers were downloaded from TCGA Pan-Cancer database for bladder and prostate carcinomas. Differential gene expressions of these markers were analyzed. Standard linear discriminant analyses were applied to establish the relative importance of these markers in lineage determination and to construct the model best in making the distinction. This study shows that all urothelial lineage genes except for the gene for uroplakin III were significantly expressed in bladder urothelial carcinomas (p\u2009&lt;\u20090.001). In descending order of importance to distinguish from prostate adenocarcinomas, genes for uroplakin II, S100P, GATA3 and thrombomodulin had high discriminant loadings (&gt;\u20090.3). All prostate lineage genes were significantly expressed in prostate adenocarcinomas(p\u2009&lt;\u20090.001). In descending order of importance to distinguish from bladder urothelial carcinomas, genes for NKX3.1, prostate specific antigen (PSA), prostate-specific acid phosphatase, prostein, and prostate-specific membrane antigen had high discriminant loadings (&gt;\u20090.3). Combination of gene expressions for uroplakin II, S100P, NKX3.1 and PSA approached 100% accuracy in tumor classification both in the training and validation sets. Mining gene expression data, a combination of four lineage markers helps distinguish between bladder urothelial carcinomas and prostate adenocarcinomas.<\/jats:p>","DOI":"10.1038\/s41598-021-85993-x","type":"journal-article","created":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T11:04:07Z","timestamp":1616583847000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Mining The Cancer Genome Atlas gene expression data for lineage markers in distinguishing bladder urothelial carcinoma and prostate adenocarcinoma"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8831-8678","authenticated-orcid":false,"given":"Ewe Seng","family":"Ch\u2019ng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,24]]},"reference":[{"key":"85993_CR1","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","volume":"79","author":"JA Witjes","year":"2021","unstructured":"Witjes, J. A. et al. European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: Summary of the 2020 guidelines. Eur. Urol. 79, 82\u2013104 (2021).","journal-title":"Eur. Urol."},{"key":"85993_CR2","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.eururo.2020.01.012","volume":"77","author":"S Gillessen","year":"2020","unstructured":"Gillessen, S. et al. Management of patients with advanced prostate cancer: Report of the advanced prostate cancer consensus conference 2019. Eur. Urol. 77, 508\u2013547 (2020).","journal-title":"Eur. Urol."},{"key":"85993_CR3","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1177\/1066896918814198","volume":"27","author":"F Sanguedolce","year":"2019","unstructured":"Sanguedolce, F. et al. Morphological and immunohistochemical biomarkers in distinguishing prostate carcinoma and urothelial carcinoma: A comprehensive review. Int. J. Surg. Pathol. 27, 120\u2013133 (2019).","journal-title":"Int. J. Surg. Pathol."},{"key":"85993_CR4","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1097\/PAS.0000000000000238","volume":"38","author":"JI Epstein","year":"2014","unstructured":"Epstein, J. I., Egevad, L., Humphrey, P. A. & Montironi, R. Best practices recommendations in the application of immunohistochemistry in the prostate: Report from the International Society of Urologic Pathology consensus conference. Am. J. Surg. Pathol. 38, e6\u2013e19 (2014).","journal-title":"Am. J. Surg. Pathol."},{"key":"85993_CR5","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/PAS.0000000000000240","volume":"38","author":"M Amin","year":"2014","unstructured":"Amin, M., Trpkov, K., Lopez-Beltran, A. & Grignon, D. Best practices recommendations in the application of immunohistochemistry in the bladder lesions: Report from the International Society of Urologic Pathology consensus conference. Am. J. Surg. Pathol. 38, 20\u201334 (2014).","journal-title":"Am. J. Surg. Pathol."},{"key":"85993_CR6","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/ng.2764","volume":"45","author":"JN Weinstein","year":"2013","unstructured":"Weinstein, J. N. et al. The cancer genome atlas pan-cancer analysis project. Nat. Genet. 45, 1113\u20131120 (2013).","journal-title":"Nat. Genet."},{"key":"85993_CR7","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41587-020-0546-8","volume":"38","author":"MJ Goldman","year":"2020","unstructured":"Goldman, M. J. et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat. Biotechnol. 38, 675\u2013678 (2020).","journal-title":"Nat. Biotechnol."},{"key":"85993_CR8","doi-asserted-by":"crossref","unstructured":"Wickham, H. GGPLOT2: Elegant Graphics for Data Analysis 2016 (Springer, 2016).","DOI":"10.1007\/978-3-319-24277-4"},{"key":"85993_CR9","unstructured":"Kassambara, A. ggpubr: \u2018ggplot2\u2019 Based Publication Ready Plots. R Package Version 0.4.0. https:\/\/CRAN.R-project.org\/package=ggpubr. (2020)."},{"key":"85993_CR10","first-page":"1","volume":"344","author":"P Sedgwick","year":"2012","unstructured":"Sedgwick, P. Multiple significance tests: The Bonferroni correction. BMJ 344, 1\u20132 (2012).","journal-title":"BMJ"},{"key":"85993_CR11","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1309\/PYQC-17CB-063T-Q07J","volume":"113","author":"O Kaufmann","year":"2000","unstructured":"Kaufmann, O., Volmerig, J. & Dietel, M. Uroplakin III is a highly specific and moderately sensitive immunohistochemical marker for primary and metastatic urothelial carcinomas. Am. J. Clin. Pathol. 113, 683\u2013687 (2000).","journal-title":"Am. J. Clin. Pathol."},{"key":"85993_CR12","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/his.12360","volume":"65","author":"SC Smith","year":"2014","unstructured":"Smith, S. C. et al. Uroplakin II outperforms uroplakin III in diagnostically challenging settings. Histopathology 65, 132\u2013138 (2014).","journal-title":"Histopathology"},{"key":"85993_CR13","first-page":"260","volume":"77","author":"R Moll","year":"1993","unstructured":"Moll, R., Laufer, J., Wu, X. R. & Sun, T. T. Uroplakin III, a specific membrane protein of urothelial umbrella cells, as a histological markers for metastatic transitional cell carcinomas. Verh. Dtsch. Ges. Pathol. 77, 260\u2013265 (1993).","journal-title":"Verh. Dtsch. Ges. Pathol."},{"key":"85993_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00000478-200301000-00001","volume":"27","author":"DC Parker","year":"2003","unstructured":"Parker, D. C. et al. Potential utility of uroplakin III, thrombomodulin, high molecular weight cytokeratin, and cytokeratin 20 in noninvasive, invasive, and metastatic urothelial (transitional cell) carcinomas. Am. J. Surg. Pathol. 27, 1\u201310 (2003).","journal-title":"Am. J. Surg. Pathol."},{"key":"85993_CR15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/path.1252","volume":"199","author":"J Olsburgh","year":"2003","unstructured":"Olsburgh, J. et al. Uroplakin gene expression in normal human tissues and locally advanced bladder cancer. J. Pathol. 199, 41\u201349 (2003).","journal-title":"J. Pathol."},{"key":"85993_CR16","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1097\/PAP.0000000000000150","volume":"24","author":"M Suryavanshi","year":"2017","unstructured":"Suryavanshi, M. et al. S100P as a marker for urothelial histogenesis: A critical review and comparison with novel and traditional urothelial immunohistochemical markers. Adv. Anat. Pathol. 24, 151\u2013160 (2017).","journal-title":"Adv. Anat. Pathol."},{"key":"85993_CR17","doi-asserted-by":"publisher","first-page":"345","DOI":"10.4132\/jptm.2016.06.14","volume":"50","author":"WJ Oh","year":"2016","unstructured":"Oh, W. J. et al. Differential immunohistochemical profiles for distinguishing prostate carcinoma and urothelial carcinoma. J. Pathol. Transl. Med. 50, 345\u2013354 (2016).","journal-title":"J. Pathol. Transl. Med."},{"key":"85993_CR18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/PAS.0b013e3182a0218f","volume":"38","author":"M Miettinen","year":"2014","unstructured":"Miettinen, M. et al. GATA3: A multispecific but potentially useful marker in surgical pathology: A systematic analysis of 2500 epithelial and nonepithelial tumors. Am. J. Surg. Pathol. 38, 13\u201322 (2014).","journal-title":"Am. J. Surg. Pathol."},{"key":"85993_CR19","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1097\/PAI.0000000000000143","volume":"23","author":"LL Hoang","year":"2015","unstructured":"Hoang, L. L., Tacha, D., Bremer, R. E., Haas, T. S. & Cheng, L. Uroplakin II (UPII), GATA3, and p40 are highly sensitive markers for the differential diagnosis of invasive urothelial carcinoma. Appl. Immunohistochem. Mol. Morphol. AIMM 23, 711\u2013716 (2015).","journal-title":"Appl. Immunohistochem. Mol. Morphol. AIMM"},{"key":"85993_CR20","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.humpath.2014.09.007","volume":"46","author":"W Tian","year":"2015","unstructured":"Tian, W. et al. Utility of uroplakin II expression as a marker of urothelial carcinoma. Hum. Pathol. 46, 58\u201364 (2015).","journal-title":"Hum. Pathol."},{"key":"85993_CR21","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1309\/AJCP1J0JPJBPSUXF","volume":"142","author":"W Li","year":"2014","unstructured":"Li, W. et al. Uroplakin II is a more sensitive immunohistochemical marker than uroplakin III in urothelial carcinoma and its variants. Am. J. Clin. Pathol. 142, 864\u2013871 (2014).","journal-title":"Am. J. Clin. Pathol."},{"key":"85993_CR22","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1111\/j.1365-2559.2007.02635.x","volume":"50","author":"P Mhawech-Fauceglia","year":"2007","unstructured":"Mhawech-Fauceglia, P. et al. Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: An immunohistochemical study using mutiple tumour tissue microarray technique. Histopathology 50, 472\u2013483 (2007).","journal-title":"Histopathology"},{"key":"85993_CR23","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1097\/PAS.0b013e31802f5d33","volume":"31","author":"AY Chuang","year":"2007","unstructured":"Chuang, A. Y. et al. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma. Am. J. Surg. Pathol. 31, 1246\u20131255 (2007).","journal-title":"Am. J. Surg. Pathol."},{"key":"85993_CR24","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/PAS.0000000000001557","volume":"45","author":"TM McDonald","year":"2021","unstructured":"McDonald, T. M. & Epstein, J. I. Aberrant GATA3 staining in prostatic adenocarcinoma: A potential diagnostic pitfall. Am. J. Surg. Pathol. 45, 341\u2013346 (2021).","journal-title":"Am. J. Surg. Pathol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-85993-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-85993-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-85993-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T05:44:32Z","timestamp":1670046272000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-85993-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,24]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["85993"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-85993-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,24]]},"assertion":[{"value":"14 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6765"}}